Company Overview - AxoGen, Inc. is a healthcare company focused on advanced medical devices for peripheral nerve repair and regeneration, utilizing a portfolio of biologically active grafts and protective devices to address complex nerve injuries [6] - The company has a market capitalization of $1.6 billion, with a revenue of $225.2 million and a net income of -$15.7 million for the trailing twelve months [4] - AxoGen's shares were priced at $30.78, reflecting a 71% increase over the past year, significantly outperforming the S&P 500, which rose about 15% in the same period [8] Financial Performance - The company reported a revenue growth of approximately 20% year-over-year, reaching $225 million, with continued double-digit expansion across its core surgical markets [10] - Despite the revenue growth, profitability remains a challenge, with a modest net loss attributed to one-time regulatory costs impacting margins [10] Product and Market Position - AxoGen develops and markets surgical solutions for peripheral nerve repair, including products like Avance Nerve Graft and AxoGuard Nerve Connector, primarily generating revenue through sales to healthcare providers and surgical centers [9] - The company serves a diverse range of medical professionals, including plastic reconstructive, orthopedic, hand, oral, and maxillofacial specialists, both in the U.S. and internationally [9] Recent Developments - DAFNA Capital Management reduced its holding in Axogen by 265,456 shares in Q4 2025, valued at approximately $6.53 million, leaving the fund with 476,826 shares worth $15.61 million at the end of the quarter [2][8] - After the sale, Axogen represented 3.63% of DAFNA's reportable assets under management, indicating a strategic portfolio adjustment rather than a loss of confidence in the company [7][8] Regulatory and Market Dynamics - The FDA approval of Avance and improved reimbursement dynamics are expected to enhance AxoGen's growth trajectory, allowing for higher procedure pricing and broader payer coverage [11] - The company is positioned in a unique space, not being a pre-revenue biotech but rather a commercial-stage business with real growth potential [7]

AxoGen (NasdaqCM:AXGN) 2026 Conference Summary Company Overview - **Company**: AxoGen - **Industry**: Biologics and Nerve Care Key Points Regulatory Approval and Market Position - AxoGen has received Biologic License Approval (BLA) for its product, which allows the company to continue its previous operations without limitations on sensory, motor, or mixed nerve applications [4][6] - The approval grants AxoGen a 12-year exclusivity period, with no other allograft products expected to enter the market during this time due to practical barriers [5][6] - The company emphasizes that nerve care is becoming increasingly recognized as a standard part of treatment pathways, contributing to its market exclusivity [7] Insurance Coverage and Reimbursement - Insurance coverage for AxoGen's product, Avance, has increased from 50% to 64%, with three primary commercial insurers still lacking coverage [8][10] - The company has satisfied all technical requirements for coverage and is in the process of formal submissions to insurers for reconsideration [11] - A significant increase in CMS reimbursement rates for outpatient settings has been noted, with a 40% increase attributed to the separation of nerve care from unrelated bundled procedures [15][21] Market Development Strategy - AxoGen is focusing on a high potential account strategy, targeting trauma centers and ensuring comprehensive education for practitioners in nerve care [27][29] - The company believes there are years of growth potential left, as many hospitals and practitioners remain unaware of nerve care solutions [28][32] - AxoGen aims to establish nerve care as a standard of care, which will drive future growth [33] Sales Force and Market Penetration - The sales force for extremities is currently 118, with plans to increase to 130, reflecting strong performance in this area [36][37] - AxoGen's flagship product, Avance, is expected to remain the largest revenue generator, with parallel growth anticipated for other products like AxoGuard [42][43] Target Markets and Future Goals - AxoGen is expanding its focus into breast surgery, with plans to train 75 surgeon pairs this year, indicating a growing interest in nerve care among surgeons [44][45] - The oral and maxillofacial segment is identified as an area with significant potential, although awareness of AxoGen's products is currently low among practitioners [52][54] Capacity and Growth Potential - The company has sufficient capacity to meet future demand, with no immediate plans for additional facilities [56][59] Additional Insights - The company is actively working to educate surgeons on the importance of preserving nerve function during procedures, which is critical for patient recovery [48][53] - AxoGen's approach to market development is methodical, focusing on building relationships and educating healthcare providers to integrate nerve care into standard practices [32][33]

He characterized the guidance as prudent given the company is “building off of a whole new base” after a stronger finish to the year, saying AxoGen wants to prove performance in new quarters and a new year while maintaining confidence that the underlying business models are elastic.Discussing the company’s 2026 outlook, management framed its guidance of at least 18% top-line growth as reflecting early-stage market penetration across multiple areas, including emergent trauma extremities and elective procedur ...

AxoGen (NasdaqCM:AXGN) 2026 Conference Summary Company Overview - **Company**: AxoGen - **Industry**: Med Tech, specifically focused on nerve care and biologics Key Points and Arguments Business Evolution and Growth - The company has evolved according to its strategic plan, with a focus on understanding its operations and setting priorities for customer creation [2][3] - AxoGen raised $142 million, netting $133 million after eliminating $68 million in debt, improving its balance sheet significantly [5] - The company reported over 20% top-line growth in Q3 and Q4 of 2025, with all business segments contributing to this growth [6][7] Market Opportunities - AxoGen is under-penetrated in various markets, particularly in breast care, where only 200 out of 1,200 potential sites are established [8] - The company aims for at least 18% top-line growth in 2026, driven by continued market penetration and customer creation models [12][14] Regulatory Milestones - The successful Biologics License Application (BLA) for AVANCE was achieved, which is expected to enhance market engagement and payer relationships [16][20] - The BLA approval allows AxoGen to re-engage with payers who previously viewed its products as experimental, potentially increasing coverage rates [25] Payer Dynamics - Current commercial coverage stands at approximately 65%, with plans to bridge the gap to full coverage by the end of the long-range plan (LRP) [24] - The company has submitted requests to payers for reevaluation based on the BLA approval, but no incremental wins are factored into the 2026 guidance [26] Operational Efficiency - The transition to a single quality system post-BLA approval is expected to yield significant operational efficiencies and improvements in gross margins starting in 2027 [19][52] - New manufacturing execution systems and Lean process improvements are being implemented to enhance production efficiency [52][57] Market Expansion and Sales Strategy - AxoGen is focusing on expanding its commercial footprint and improving sales rep productivity, which has shown positive results since 2025 [34][38] - The company emphasizes the importance of awareness and education in nerve care to drive market adoption [36] Future Growth Areas - AxoGen is exploring expansion into the prostate market, with initial pilot programs aimed at demonstrating predictable outcomes in nerve preservation during prostatectomies [45][49] - The company is optimistic about the potential for significant revenue from the prostate market, although it is still early to quantify its impact [50] Gross Margin Considerations - Initial sales of the biologic labeled AVANCE product will carry higher costs, leading to gross margin pressure in Q2, but improvements are expected as efficiencies are realized [52][53] Investment Opportunity - AxoGen is positioned as a leader in the nerve care market, with the potential for double-digit growth driven by its unique product offerings and market demand [60] - The company’s focus on improving patient outcomes and operational efficiency presents a compelling investment opportunity in the med tech space [61] Additional Important Insights - The company is committed to rigorous execution and scaling its operations effectively, recognizing the challenges that come with growth [39][40] - AxoGen's approach to market development is characterized by traditional customer creation and awareness-building strategies, which are yielding positive results [38]

PresentationAnd so with that, I'll pass it off to Mike, who will give a presentation, and then we'll do some Q&A at the end.We'll get started. Welcome again to the 47th Annual Raymond James Institutional Investors Conference. My name is Jayson Bedford. I cover the med tech sector here. And it's really our privilege to have with us today the senior management team of Axogen, AXGN. It's a name that we've liked for a little bit here, and they've done a good job of executing. So with this, we have the company's ...

Core Insights - AxoGen aims to establish the restoration of peripheral nerve function as a standard of care, focusing on market development and addressing gaps in awareness and payer coverage [4][10][12] Market Development Focus - The company has prioritized four key areas for market development, emphasizing the need for consistent integration of peripheral nerve assessment and repair in clinical pathways [2][5] - AxoGen's growth strategy is driven by addressing the current oversight of nerve care in trauma and surgical interventions, which often leads to long-term functional deficits for patients [2][3] Product Portfolio - AxoGen's primary product, the AVANCE Nerve Graft, is the first approved biologic therapeutic solution for treating nerve discontinuities, accounting for approximately 60% of the company's revenue [8][12] - The product portfolio also includes AxoGuard products, which support surgical procedures and enhance nerve reconstruction [8] Financial Performance and Guidance - The company projects at least 18% revenue growth for the year, translating to approximately $266 million, with gross margins expected between 74% and 76% [6][14] - AxoGen has completed a $142 million financing round, which has strengthened its balance sheet and supports future growth initiatives [15] Reimbursement and Adoption Barriers - AxoGen faces a 35% gap in commercial lives covered for nerve repair, with ongoing efforts to update coverage guidelines from major payers [5][11] - While Medicare provides full coverage for nerve care, many injuries occur in populations with commercial insurance, complicating broader adoption [10][11] FDA Approval and Strategic Positioning - The recent FDA Biologics License Application (BLA) approval for the AVANCE Nerve Graft validates the product and enhances AxoGen's credibility with payers and physicians [6][12] - The approval allows the company to consolidate its biologics quality system and pursue new clinical studies to support its standard-of-care goals [12][13] Prostate Care Evaluation - AxoGen is evaluating the potential for prostate care procedures, assessing whether they can be taught effectively and yield reproducible outcomes before scaling commercial efforts [1][16]

AxoGen Conference Call Summary Company Overview - **Company**: AxoGen, Inc. (Ticker: AXGN) - **Industry**: Med Tech, specifically focused on peripheral nerve repair and restoration Core Points and Arguments 1. **Mission and Purpose**: AxoGen aims to make the restoration of peripheral nerve function an expected standard of care, addressing a significant gap in current medical practices [2][4] 2. **Market Opportunities**: The company has identified four priority areas for market development: - Extremities (largest opportunity, primarily trauma-related) - Breast reconstruction (restoring sensation post-mastectomy) - Oral maxillofacial head and neck procedures (oncological and elective) - Prostate care (under evaluation for future development) [5][6][8] 3. **Growth Projections**: AxoGen anticipates a growth rate of 15%-20% annually over the next 3-5 years, driven by the first three areas of focus, excluding prostate care for now [9][13] 4. **Product Portfolio**: The Avance Nerve Graft is highlighted as the first-ever approved biologic therapeutic solution for nerve discontinuities, accounting for approximately 60% of revenue, with Axoguard making up the remainder [10][11] 5. **Barriers to Adoption**: Key challenges include lack of awareness, insufficient care guidelines, and incomplete payer networks, which hinder the adoption of nerve care as a standard practice [12][20] 6. **Regulatory Milestone**: The recent FDA approval of the Biologics License Application (BLA) for Avance is expected to enhance market credibility and facilitate discussions with payers and healthcare providers [27][28] 7. **Reimbursement Strategy**: AxoGen aims for near-universal coverage by 2028, with ongoing efforts to meet payer requirements for coverage [34][35] 8. **Financial Position**: The company recently raised $142 million, using proceeds to pay off $68 million in debt, which is expected to improve cash flow and profitability [37] 9. **R&D Investment**: AxoGen invests approximately 14% of its turnover in R&D, with a revenue guidance of at least $266 million for the year and gross margins projected between 74%-76% [21][44] Additional Important Insights 1. **Clinical Evidence**: The company emphasizes the need for robust clinical evidence to support its standard of care aspirations, particularly in new markets [30] 2. **Quality Systems**: Transitioning to a biologics quality system post-BLA approval will streamline operations and reduce resource intensity, allowing for better investment in manufacturing improvements [32] 3. **Future Developments**: The company is exploring the teachability of nerve repair procedures in prostate care, with initial clinical data expected in the second half of the year [41][42] 4. **Long-term Vision**: AxoGen positions itself as a leader in the peripheral nerve repair market, with a commitment to improving health outcomes and quality of life for patients [22][23] This summary encapsulates the key points discussed during the AxoGen conference call, highlighting the company's strategic direction, market opportunities, and financial outlook.

分组1 - Axogen, Inc. (AXGN) reported a 4Q25 non-GAAP EPS of $0.07, missing expectations by approximately $0.03 [1] - Revenue for the quarter was $59.9 million, aligning with estimates and reflecting a year-over-year growth of 21.3% [1]

Achieved a critical regulatory milestone with FDA approval of the Biologics License Application (BLA) for Avance, establishing it as the first and only approved biologic therapeutic for peripheral nerve discontinuities. Delivered 20.2% full-year revenue growth driven by double-digit expansion across all three target markets: Extremities, Oral Maxillofacial, and Breast. Reached a financial inflection point characterized by positive cash flow and improved profitability, enabling concentrated market deve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ Form 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ ...